INTRODUCTION
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thromboembolic events associated with antiphospholipid antibodies. The 2023 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria emphasize the integration of autoimmune serology and clinical manifestations, requiring at least one laboratory and one clinical criterion for diagnosis[1]. APS may occur as a primary disorder or secondary to autoimmune diseases such as rheumatoid arthritis (RA), where prevalence ranges from 5% to 75%[2].
Previous reports described APS onset after anti-tumour necrosis factor (TNF)-α therapy, suggesting that biologic agents may promote autoantibody formation or thrombosis in predisposed patients[3]. Arterial thrombosis is one of the main manifestations of APS and often involves unusual anatomical locations. Hepatic thrombosis is the most common gastrointestinal macrovascular involvement and splenic infarction is rare; therefore, it may represent the first clinical sign of APS[4].
We report a case of APS presenting as splenic infarction after temporary suspension of tocilizumab in a multifailure RA patient previously exposed to anti-TNF-α agents and rituximab.
CASE DESCRIPTION
A 53-year-old man with type II diabetes mellitus was diagnosed with RA in 2003, which began with polyarthritis involving wrists, elbows, ankles, and small hand joints, associated with rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) positivity. Initial therapy with methotrexate at 15 mg/week, due to scarce benefit, was combined with infliximab in 2006 and then, in 2011, with rituximab, due to RA disease flare, and discontinued after 2 years due to poor response. In 2013 laboratory tests showed weak positivity for lupus anticoagulant (LAC) and immunoglobulin (Ig)G anticardiolipin antibodies (aCL IgG), while subsequent controls were negative.
From January 2013 the patient received tocilizumab 8 mg/kg monthly combined with methotrexate, with good clinical response. Tocilizumab was interrupted from March to June 2018 for minor orthopaedic procedures, including surgical treatment of tenosynovitis and elbow bursectomy complicated by skin abscess. During this period, the patient continued only methotrexate therapy.
In August 2018, he developed sudden right hypochondrial pain. Abdominal computed tomography (CT) scan demonstrated a hypodense splenic lesion compatible with splenic infarction (Fig. 1).
Laboratory findings showed D-dimer 2264 ng/ml (<500), fibrinogen 612 mg/dl (>400), and C-reactive protein (CRP) 16.9 mg/dl (<0.2), supporting an ischemic process. Rheumatologic evaluation demonstrated triple positivity for APS laboratory criteria (LAC, aCL IgG, anti-beta-2glycoproteinI (aB2GPI) IgG) associated with the arterial thrombotic event, leading to APS diagnosis. At hospitalization, disease activity score (DAS28) was 4.03; RF and ACPA were markedly elevated, antinuclear antibodies (ANA) showed a low-titer granular pattern, while platelet count and complement fractions were normal (Table 1).
The patient was discharged on methotrexate, baricitinib 4 mg/day, and warfarin with an international normalized ratio target range of 2.5–3.5. Steroid therapy was gradually tapered and discontinued in 2020. During follow-up, no recurrent thrombotic events occurred while anticoagulation was maintained (Fig.
2).
DISCUSSION
APS accounts for approximately 5.6% of splenic infarction cases[5], and its coexistence with RA is plausible[2]. However, splenic infarction as the first clinical manifestation of APS during immunosuppressive treatment remains uncommon. This case highlights important aspects of RA management, including molecular immunology, pharmacologic modulation of autoimmunity, and thrombotic risk assessment.
Tocilizumab may have acted as a suppressor of autoreactive B-cell clones producing antiphospholipid antibodies (aPLs). Its discontinuation induced a marked serological rebound, progressing from isolated transient positivity to persistent triple positivity, suggesting a central role of interleukin (IL)-6 in controlling pathogenic autoantibody production. High ACPA titers may also have contributed to the prothrombotic state.
ACPAs are associated with severe RA, extra-articular manifestations, and accelerated atherosclerosis[6]. Recent evidence indicates that ACPAs activate macrophages and neutrophils through neutrophil extracellular trap formation, promoting endothelial dysfunction and thrombosis[7]. In this setting, ACPAs may have provided a pro-inflammatory scaffold favouring antiphospholipid-mediated thrombosis and splenic infarction[8].
The clinical course supports the “Two-Hit” hypothesis of APS. The first hit consisted of biologic withdrawal, leading to increased CRP and fibrinogen and creating a hyper-reactive vascular environment. The second hit was represented by surgical stress and bacterial superinfection, which probably triggered massive aPL production and thrombosis[9].
The absence of hypocomplementemia and thrombocytopenia excluded rheumatoid vasculitis or catastrophic APS, supporting a primary arterial thrombotic event. This case suggests that even isolated previous aPL positivity should not be underestimated in RA patients with high ACPA titers before biologic discontinuation. Suspension of tocilizumab for more than 3 months likely resulted in complete IL-6 inhibition washout[10].
These findings raise questions regarding the necessity of prolonged biologic withdrawal before minor surgery and emphasize the importance of thrombotic risk profiling in patients with previous aPL positivity. Monitoring inflammatory markers such as CRP and erythrocyte sedimentation rate during biologic suspension and minimizing withdrawal time, also through multidisciplinary consultation, may help reduce thrombotic complications. Finally, despite the patient’s “B-cell oriented” immunologic profile and the previous limited efficacy of rituximab, baricitinib was introduced after anticoagulation because of patient preference for oral therapy.
No recurrent thrombosis occurred, suggesting that Janus kinase inhibitors may be a safe therapeutic option in selected patients when associated with adequate anticoagulation and careful monitoring.